Sugi Predict

Sugi Predict / Compounds / SCHEMBL760018

SCHEMBL760018

SCHEMBL760018

Nc1n[nH]c2cccc(Br)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 6/20 0.61
▸ GAA P10253 2/20 0.61
▸ KDR P35968 5/20 0.60
▸ ROCK1 Q13464 4/20 0.60
▸ JAK2 O60674 4/20 0.60
▸ LCK P06239 3/20 0.60
▸ CSF1R P07333 3/20 0.60
▸ FGFR1 P11362 3/20 0.60
▸ PRKACA P17612 3/20 0.60
▸ PLK4 O00444 2/20 0.60
▸ AURKA O14965 2/20 0.60
▸ CDK1 P06493 2/20 0.60
▸ LYN P07948 2/20 0.60
▸ SRC P12931 2/20 0.60
▸ RPS6KB1 P23443 2/20 0.60
▸ CDK2 P24941 2/20 0.60
▸ MARK3 P27448 2/20 0.60
▸ BLK P51451 2/20 0.60
▸ MARK2 Q7KZI7 2/20 0.60
▸ AURKB Q96GD4 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30566149 1.00 PDPK1 (0.61) PDPK1GAAKDRROCK1JAK2
SCHEMBL628649 0.79 PDPK1 (0.66) PDPK1GAAKDRROCK1JAK2
SCHEMBL30065304 0.79 PDPK1 (0.66) PDPK1GAAKDRROCK1JAK2
SCHEMBL28919844 0.79 PDPK1 (0.46) PDPK1GAAKDRROCK1JAK2
SCHEMBL569660 0.76 GAA (0.61) PDPK1GAAKDRROCK1JAK2
SCHEMBL185907 0.76 GAA (0.61) PDPK1GAAKDRROCK1JAK2
SCHEMBL7736987 0.76 PDPK1 (0.61) PDPK1GAAKDRROCK1JAK2
SCHEMBL12928484 0.76 PDPK1 (0.61) PDPK1GAAKDRROCK1JAK2
SCHEMBL186280 0.76 GAA (1.00) PDPK1GAAKDRROCK1JAK2
SCHEMBL10368038 0.76 PDPK1 (0.61) PDPK1GAAKDRROCK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111513-A1 COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY NURIX THERAPEUTICS, INC. (US) 2025-05-30 — — WO disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
EP-4452977-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-06-02 — — US disclosed
US-20130035324-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2013-02-07 — — US disclosed
US-20130035324-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2013-02-07 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
CN-101437519-A Indazole compounds ABBOTT LAB (US) 2009-05-20 — — CN disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 — — EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof PIK3CA, PIK3CD, PIK3CB PDPK1 12/4885GAA 423/4885KDR 1595/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 PDPK1 856/4885GAA 358/4885KDR 3628/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 PDPK1 684/4885GAA 694/4885KDR 2442/4885
US-10668071-B2 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use SERPINB6, SERPINC1, SERPINE1 PDPK1 1304/4885GAA 3619/4885KDR 534/4885
US-20130035324-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PDPK1 12/4885GAA 423/4885KDR 1595/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 PDPK1 300/4885GAA 1288/4885KDR 1698/4885
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF MTOR, AKT2, MTMR1 PDPK1 13/4885GAA 315/4885KDR 2631/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 PDPK1 856/4885GAA 358/4885KDR 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.